Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial

BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral role of quercetin, and on its described anti-blood clotting, anti-inflammatory and antioxidant properties, we hypothesize that...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Pierro, Francesco, Iqtadar, Somia, Khan, Amjad, Ullah Mumtaz, Sami, Masud Chaudhry, Mohsin, Bertuccioli, Alexander, Derosa, Giuseppe, Maffioli, Pamela, Togni, Stefano, Riva, Antonella, Allegrini, Pietro, Khan, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238537/
https://www.ncbi.nlm.nih.gov/pubmed/34194240
http://dx.doi.org/10.2147/IJGM.S318949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238537/
https://www.ncbi.nlm.nih.gov/pubmed/34194240
http://dx.doi.org/10.2147/IJGM.S318949

Ejemplares similares